Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases
Biogen Inc. (BIIB)
Last biogen inc. earnings: 4/22 07:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
biogen.com/en_us/investors.html
Company Research
Source: Business Wire
Transaction builds upon the productive collaboration that produced SPINRAZA® as well as two antisense drug candidates currently in the clinic, with the potential to advance up to seven more drug candidates to the clinic within the next two years The antisense platform developed by Ionis is an established and validated gene-based therapeutic modality, as evidenced by the success of SPINRAZA, with the potential to address numerous neurological diseases that are currently untreatable Biogen will pay Ionis $1 billion in cash, including an equity investment in Ionis stock and an upfront payment, representing one of the most significant discovery stage collaborations in the industry CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)-- Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) announced today they have expanded their strategic coll
Show less
Read more
Impact Snapshot
Event Time:
BIIB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIIB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIIB alerts
High impacting Biogen Inc. news events
Weekly update
A roundup of the hottest topics
BIIB
News
- What's in Store for Biogen (BIIB) This Earnings Season? [Yahoo! Finance]Yahoo! Finance
- Gear Up for Biogen (BIIB) Q1 Earnings: Wall Street Estimates for Key Metrics [Yahoo! Finance]Yahoo! Finance
- Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $290.00 to $270.00. They now have an "outperform" rating on the stock.MarketBeat
- Alzheimer's Therapeutics Market Size Expected to Surpass USD 8.18 Bn by 2032 [Yahoo! Finance]Yahoo! Finance
- Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at UBS Group AG from $250.00 to $214.00. They now have a "neutral" rating on the stock.MarketBeat
BIIB
Earnings
- 2/14/24 - Miss
BIIB
Sec Filings
- 4/12/24 - Form PRE
- 4/3/24 - Form 4
- 4/3/24 - Form 4
- BIIB's page on the SEC website